NCT03102242 - Atezolizumab Immunotherapy in Patients With Advanced NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

June 1, 2020

Study Completion Date

October 1, 2022

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Atezolizumab

Single arm phase II trial of induction immunotherapy with anti-PD-L1 for patients with unresectable stage III NSCLC and PS 0-1.

Trial Locations (13)

SUNY Upstate Medical University, Syracuse

Lankenau Medical Center, Wynnewood

University of Virginia Cancer Center, Charlottesville

Prisma Health Greenville Memorial Hospital, Greenville

Ohio State University James Cancer Center, Columbus

Saint Joseph Mercy Hospital, Ann Arbor

Metro MN Community Oncology Research Consortium, Minneapolis

The University of Chicago Medical Center, Chicago

Washington University School of Medicine, St Louis

Mayo Clinic Hospital, Phoenix

UCSD Moores Cancer Center, La Jolla

EMMC Cancer Care, Brewer

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

Alliance Foundation Trials, LLC.

OTHER